Pancreatic Cancer Diagnosis With FAPI-PET Imaging
Recruiting
Phase 2
Phase 3
Interventional Study
Positron Emission Tomography
Pancreatic Cancer
FAPI
Diagnostics
Recurrent Pancreatic Cancer
Oncologic Surgery
Imaging, Diagnostic
Staging
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 85
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 100 (estimated)
- Sponsor
- Turku University Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET/CT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and di…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Suspected primary or recurrent pancreatic cancer
* Subjects must be male or female aged 18-85 years.
* WHO performance score 0-2.
* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.
Exclusion Criteri…
Contacts